We are live on ! Find out more
QTRX icon

Quanterix

Positive
Neutral
Negative
Sentiment 3-Months
Positive 6.7%
Neutral 86.7%
Negative 6.7%

Positive
Seeking Alpha
7 hours ago
Quanterix: Trading Below 1x Sales Despite A Changing Story
Quanterix is transitioning from persistent losses to a turnaround, driven by a new, highly experienced management team post-Akoya acquisition. QTRX targets cash flow breakeven in H2 2026, leveraging cost synergies, commercial execution, and a large installed base for recurring revenue. The Alzheimer's blood test and broader biomarker platform offer significant growth potential, though execution and adoption risks remain.
Quanterix: Trading Below 1x Sales Despite A Changing Story
Neutral
Business Wire
4 days ago
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
6 days ago
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer's testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix's five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer's disease through a comprehensive, blood-based assessment. The announcements inc.
Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages
Neutral
Business Wire
1 month ago
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15, 2026, inducement grants (the “Inducement Grants”) were made to three employees in connection with the commencement of their employment. The Inducement Grants consisted of 336,804 restricted stock units (“RSUs”) representing 336,804 shares of Quanterix commo.
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
1 month ago
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral
Business Wire
1 month ago
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's st.
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
Neutral
Business Wire
1 month ago
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hire underscores Quanterix's commitment to transforming its Diagnostics opportunity into a key component of the company's future growth strategy. Starting with Alzheimer's Disease Diagnostics, Al.
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
Neutral
Business Wire
1 month ago
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Com.
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Neutral
Business Wire
1 month ago
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on May 15, 2026, an inducement grant (the “Inducement Grant”) was made to Anthony Catalano in connection with the commencement of his employment as the Chief Operating Officer of the Company. The Inducement Grant consists of restricted stock units (“RSUs”) covering 141.
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Business Wire
2 months ago
Quanterix Announces Planned Transition of Chief Financial Officer
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer (“CFO”) will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition. "Vandana has made impactful contributions to Quanterix since joining the Co.
Quanterix Announces Planned Transition of Chief Financial Officer